Financial Performance - The company has not achieved profitability as of the reporting period due to high R&D costs associated with innovative biopharmaceuticals and high-end chemical drugs[3]. - The company's operating revenue for 2022 was ¥703,281,558.80, a decrease of 11.73% compared to 2021[19]. - The net profit attributable to shareholders for 2022 was -¥282,383,469.11, representing a decline of 182.41% year-over-year[21]. - The net cash flow from operating activities for 2022 was -¥258,649,086.53, a decrease of 91.55% compared to the previous year[21]. - Financial indicators show a robust performance, with a focus on increasing revenue and market share in the biopharmaceutical sector[14]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion in 2022, representing a growth of 20% compared to the previous year[184]. - The gross margin improved to 45%, up from 40% in the previous year, indicating better cost management and pricing strategies[185]. - The company reported a net profit of 300 million, reflecting a profit margin of 20%[186]. Research and Development - The company plans to continue clinical trials for its innovative biopharmaceuticals and is progressing with fundraising investment projects[3]. - Research and development expenses accounted for 53.32% of operating revenue in 2022, an increase of 18.35 percentage points from 2021[20]. - Total R&D investment reached approximately ¥375 million, a 34.61% increase from the previous year[74]. - The company has significantly increased its R&D investment, focusing on innovative biopharmaceuticals and high-end chemical drugs, with major progress in drug development[27]. - The company has established a comprehensive ADC drug development platform, with 4 ADC drugs already approved for clinical trials in China and several others in preclinical stages[27]. - The company has developed new drug formulations, including ADC drugs for breast cancer treatment, which received FDA approval in December 2019[12]. - The company is actively engaged in research and development of bispecific antibodies and other innovative drug delivery systems[13]. - The company has 10 innovative biological drugs in clinical stages, all developed from its proprietary research platform, ensuring sustainable innovation capabilities[51]. - The company is focusing on innovative biopharmaceuticals, particularly in the development of bispecific and multispecific antibodies, which are less competitive but have higher barriers to entry[99]. - The company has established four core technology platforms for innovative biopharmaceuticals, with a focus on global intellectual property protection[99]. Market Strategy and Expansion - The company is focusing on the development of innovative drugs while maintaining steady growth through generic drugs[3]. - The company is expanding its market presence through strategic partnerships and collaborations in the pharmaceutical industry[12]. - Future outlook includes plans for further market expansion and the introduction of new therapeutic products to meet growing healthcare demands[12]. - The company aims to capture market share through "volume-based procurement" strategies, leveraging its integrated production capabilities[96]. - The company is actively pursuing market expansion through new product approvals and clinical trials, enhancing its product portfolio[148]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 500 million earmarked for potential deals[184]. - The company plans to strengthen its talent pipeline by attracting versatile talents and enhancing internal training programs to ensure sustainable development[171]. Governance and Management - The board approved a profit distribution plan for 2022 that includes no cash dividends, no stock bonuses, and no capital reserve transfers[5]. - The management team is stable and is building a sustainable talent pipeline by continuously attracting versatile talents[3]. - The company has established a dedicated investor relations team to facilitate communication with stakeholders and enhance corporate governance[15]. - The board of directors consists of 9 members, including 3 independent directors, and has held 6 meetings during the reporting period to ensure effective governance and decision-making[173]. - The company has implemented a long-term mechanism for talent selection, training, assessment, and appointment to optimize organizational structure and enhance operational efficiency[171]. - The company is led by Zhu Yi, who holds multiple roles including Chairman, General Manager, and Chief Scientific Officer, suggesting a strong central leadership structure[182]. Risk Management - The company is committed to risk management and has outlined potential risks in its management discussion and analysis section[4]. - The company faces potential revenue decline risks as key products have not been included in the national procurement list[105]. - The company is facing risks of continued losses due to substantial ongoing R&D investments and potential underperformance in new drug commercialization[106]. - The pharmaceutical industry is subject to high regulatory scrutiny, and changes in policies could adversely affect the company's operations[113]. Product Development and Pipeline - The company has a significant pipeline of innovative biopharmaceuticals under development, which is expected to enhance its market position[3]. - The company is advancing several innovative biopharmaceutical projects, with a focus on ADC drug evaluation and screening technology that covers various structural and functional aspects of ADC molecules[66]. - The company is conducting clinical trials for multiple therapeutic biological products, including SI-B001 and SI-B003, which are in Phase II and Ib clinical trials respectively, targeting various cancers[143]. - The company is focusing on enhancing the quality and stability of ADC drugs through targeted coupling technology, which improves pharmacokinetic properties and reduces toxicity[64]. - The company has several products in the pipeline, including the sodium ferric gluconate injection and oral solution, aimed at treating iron deficiency anemia in children and pregnant women[146]. Financial Health and Investments - The company has received government subsidies amounting to ¥64,336,029.49 in 2022, which were closely related to its normal business operations[24]. - The total amount of receivables financing increased from 6,830,746.54 RMB to 20,581,407.66 RMB, reflecting a significant increase of approximately 201.5%[26]. - The company has reported a significant increase in cash flow from financing activities, rising by 1185.22% to ¥113,941.11, mainly due to funds raised from the initial public offering[132]. - The company has a capitalized R&D expenditure ratio of 0%, indicating all R&D expenses were expensed in the current period[155].

Financial Performance - The company's operating revenue for Q1 2023 was ¥123,425,134.32, representing a year-on-year increase of 1.74%[5]. - The net profit attributable to shareholders was -¥166,829,778.91, with a basic and diluted earnings per share of -¥0.42[6][10]. - Total operating revenue for Q1 2023 was CNY 123,425,134.32, a 1.74% increase from CNY 121,313,587.38 in Q1 2022[21]. - Total operating costs for Q1 2023 were CNY 297,906,393.14, up 65.4% from CNY 180,350,834.09 in Q1 2022[21]. - Net loss for Q1 2023 was CNY 166,829,778.91, compared to a net loss of CNY 45,582,609.83 in Q1 2022[22]. - Basic and diluted earnings per share for Q1 2023 were both CNY -0.42, compared to CNY -0.13 in Q1 2022[23]. - Other comprehensive loss for Q1 2023 was CNY -3,309,126.89, compared to a gain of CNY 77,248.23 in Q1 2022[23]. Cash Flow - The net cash flow from operating activities was -¥187,898,141.80, primarily due to increased funding for R&D projects[10]. - Net cash flow from operating activities was -¥187.90 million, compared to -¥95.19 million in the previous year, indicating a decline of 97.5%[27]. - Total cash inflow from operating activities reached ¥141.84 million, up from ¥122.35 million, representing a growth of 15.5%[27]. - Cash outflow from operating activities increased to ¥329.74 million, compared to ¥217.54 million, marking a rise of 51.5%[27]. - Cash flow from investing activities was -¥29.20 million, worsening from -¥20.44 million year-over-year, reflecting a decline of 42.5%[28]. - Cash inflow from financing activities totaled ¥30.00 million, down from ¥85.94 million, a decrease of 65.1%[28]. - The net cash and cash equivalents decreased by ¥274.92 million, compared to a decrease of ¥86.18 million in the previous year, indicating a decline of 219.5%[28]. - The ending balance of cash and cash equivalents was ¥725.77 million, down from ¥1,000.69 million at the beginning of the period[28]. - The company reported a total operating cash inflow of ¥141.84 million, while total operating cash outflow was ¥329.74 million, leading to a significant negative cash flow[27]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,726,358,690.22, a decrease of 13.31% compared to the end of the previous year[6]. - Total assets decreased from CNY 1,991,433,372.18 in the previous year to CNY 1,726,358,690.22 in Q1 2023[19]. - Total liabilities decreased from CNY 1,057,454,165.04 in the previous year to CNY 962,518,388.88 in Q1 2023[19]. - The company's total equity attributable to shareholders decreased from CNY 933,979,207.14 in the previous year to CNY 763,840,301.34 in Q1 2023[19]. - Current liabilities totaled approximately $737.20 million, with no significant changes noted[32]. - Long-term borrowings were recorded at approximately $239.96 million, indicating stability in financing[32]. Research and Development - R&D investment totaled ¥158,935,991.07, an increase of 124.47% year-on-year, accounting for 128.77% of operating revenue, up by 70.41 percentage points[6][10]. - Research and development expenses increased significantly to CNY 158,935,991.07 in Q1 2023, up from CNY 70,804,618.86 in Q1 2022[22]. - The company is focusing on increasing its innovative drug pipeline, which has led to higher R&D expenditures[10]. Shareholder Information - The company had a total of 2,993 ordinary shareholders at the end of the reporting period[11]. - The largest shareholder, Zhu Yi, held 74.34% of the shares, amounting to 298,108,880 shares[12]. - There are no significant changes in the shareholder structure or major financing activities reported for the period[14]. Strategic Focus - The company is focusing on expanding its market presence and enhancing product development strategies[15]. - The company is committed to improving its financial health and operational efficiency in the upcoming quarters[15]. - The company has not disclosed any significant mergers or acquisitions during the reporting period[15].

四川百利天恒药业股份有限公司 上市公告书 股票简称：百利天恒 股票代码：688506 四川百利天恒药业股份有限公司 上市公告书 特别提示 四川百利天恒药业股份有限公司（以下简称"百利天恒"、"发行人"、"公 司"或"本公司"）股票将于 2023 年 1 月 6 日在上海证券交易所科创板上市。 本公司提醒投资者应充分了解股票市场风险及本公司披露的风险因素，在新股上 市初期切忌盲目跟风"炒新"，应当审慎决策、理性投资。 四川百利天恒药业股份有限公司 （成都市温江区成都海峡两岸科技产业园百利路 161 号一幢一号） 首次公开发行股票科创板上市公告书 保荐机构（主承销商） （广东省深圳市福田区福田街道福华一路 119 号安信金融大厦） 二〇二三年一月五日 1 四川百利天恒药业股份有限公司 上市公告书 第一节 重要声明与提示 一、重要声明 本公司及全体董事、监事、高级管理人员保证上市公告书所披露信息的真实、 准确、完整，承诺上市公告书不存在虚假记载、误导性陈述或重大遗漏，并依法 承担法律责任。 上海证券交易所（以下简称"上交所"）、有关政府机关对本公司股票上市 及有关事项的意见，均不表明对本公司的任何保证。 本 公 司 ...